CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
Launched by RSPR PHARMA AB · Feb 28, 2012
Trial Information
Current as of May 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented diagnosis of dystrophinopathy
- Exclusion Criteria:
- • Severe functional impairment
About Rspr Pharma Ab
RSPR Pharma AB is an innovative biotechnology company dedicated to advancing therapeutic solutions in the field of medicine. With a strong focus on research and development, RSPR Pharma specializes in the discovery and commercialization of novel drug candidates aimed at addressing unmet medical needs across various disease areas. The company is committed to rigorous clinical trials and adheres to the highest standards of regulatory compliance, ensuring the safety and efficacy of its products. Leveraging a team of experienced professionals and cutting-edge technologies, RSPR Pharma strives to enhance patient outcomes and contribute to the advancement of healthcare globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
T Sejersen, MD PhD
Principal Investigator
Karolinska University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials